4.7 Article

Cross-species analysis of enhancer logic using deep learning

Journal

GENOME RESEARCH
Volume 30, Issue 12, Pages -

Publisher

COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/gr.260844.120

Keywords

-

Funding

  1. European Research Council [724226_cis-CONTROL]
  2. Catholic University of Leuven [C14/18/092]
  3. Foundation Against Cancer [2016-070]
  4. Fonds Wetenschappelijk Onderzoek [1S03317N]
  5. Kom op tegen Kanker (Stand up to Cancer
  6. the Flemish Cancer Society)
  7. Stichting tegen Kanker (Foundation against Cancer
  8. the Belgian Cancer Society)
  9. BRC-Anim PIA1 funding (2012-2022) [ANR-11-INBS-0003]

Ask authors/readers for more resources

Deciphering the genomic regulatory code of enhancers is a key challenge in biology because this code underlies cellular identity. A better understanding of how enhancers work will improve the interpretation of noncoding genome variation and empower the generation of cell type-specific drivers for gene therapy. Here, we explore the combination of deep learning and cross-species chromatin accessibility profiling to build explainable enhancer models. We apply this strategy to decipher the enhancer code in melanoma, a relevant case study owing to the presence of distinct melanoma cell states. We trained and validated a deep learning model, called DeepMEL, using chromatin accessibility data of 26 melanoma samples across six different species. We show the accuracy of DeepMEL predictions on the CAGI5 challenge, where it significantly outperforms existing models on the melanoma enhancer of IRF4. Next, we exploit DeepMEL to analyze enhancer architectures and identify accurate transcription factor binding sites for the core regulatory complexes in the two different melanoma states, with distinct roles for each transcription factor, in terms of nucleosome displacement or enhancer activation. Finally, DeepMEL identifies orthologous enhancers across distantly related species, where sequence alignment fails, and the model highlights specific nucleotide substitutions that underlie enhancer turnover. DeepMEL can be used from the Kipoi database to predict and optimize candidate enhancers and to prioritize enhancer mutations. In addition, our computational strategy can be applied to other cancer or normal cell types.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available